RIO programme: placebo-subtracted change for multiple CMR
factors
SBP (mmHg)
Waist circumference (cm)
Triglycerides (%)
HDL-cholesterol (%)
*
*
*
*
%
*p<0.001
*
*
*
*
*p<0.001
*
*p<0.001
cm
-3.6
*
-4.2
*
-4.7
*
-3.3
0
-1
-2
-3
-4
-5
-6
p<0.05
p<0.05
NS
NS
-0.2
-1.2
-1.7
-2.3
mmHg
0
-0.5
-1
-1.5
-2
-2.5
-3
0.5
↓ HbA1C
Pi-Sunyer FX et al, 2006;
Després JP et al, 2005; Van Gaal L et al, 2005
-20
-15
-10
-5
0
5
10
7.2
8.9
8.1
8.4
-6
-5
-4
-3
-2
-1
0
-
13.2
-
15.1
-
12.4
-
16.4
-20
-15
-10
-5
0
5
10
-3
-2,5
-2
-1,5
-1
-0,5
0
0,5
↓ CRP
Adiponectin
RIO programme:
placebo-subtracted change for CMR factors
The prevalence of
individual diagnostic criteria for the metabolic syndrome was also evaluated
before and after treatment in a pooled analysis from the four RIO trials. A
consistent significant improvement in waist circumference, HDL-C and
triglycerides was seen vs. placebo (p<0.001 in all cases) in the four
trials. The effects of rimonabant on systolic blood pressure were significant
vs placebo in the RIO Diabetes and RIO Lipids trials (p<0.05).
The differences in
the effect of rimonabant on blood pressure between the trials likely reflects
differences in the hypertensive status of the trial populations at baseline.
In general, rimonabant exerted larger effects on blood pressure in
populations with high pressure at baseline factors (BP >140/90).
Overall, these data
show that rimonabant consistently improved multiple of cardiometabolic risk
associated.